MARKET

TROV

TROV

Trovagene
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.340
-0.010
-0.74%
After Hours: 1.340 0 0.00% 17:06 12/13 EST
OPEN
1.360
PREV CLOSE
1.350
HIGH
1.360
LOW
1.280
VOLUME
48.07K
TURNOVER
--
52 WEEK HIGH
9.65
52 WEEK LOW
0.8800
MARKET CAP
10.37M
P/E (TTM)
-0.4033
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of TROV and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

TROV News

  • Efficacy, Durability of Response and Safety of Onvansertib Demonstrated in Completed Phase 1b Trial in AML Patients Presented in Oral Session at ASH
  • PR Newswire.5d ago
  • Trovagene Announces Data Showing Ability of Onvansertib to Rescue Venetoclax-Resistance in Acute Myeloid Leukemia (AML)
  • PR Newswire.12/04 13:00
  • The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More
  • Benzinga.12/01 14:30
  • Benzinga Pro's Top 5 Stocks To Watch For Thurs., Nov. 14, 2019: NVDA, SINA, DDS, TROV, AMRN
  • Benzinga.11/14 13:44

More

Industry

Medical Equipment, Supplies & Distribution
+0.35%
Healthcare Equipment & Supplies
+0.24%

Hot Stocks

Name
Price
%Change

About TROV

Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers. PCM-075 developed high selectivity to PLK1, to be administered orally, and to have a relatively short drug half-life of approximately 24 hours compared to other PLK inhibitors. PCM-075 has completed a safety study in patients with advanced metastatic solid tumors with a phase Ib/II clinical trial in patients with AML underway.
More

Webull offers TrovaGene Inc (TROV) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.